Dear Client,
Kantar Health is proud to present the latest update of CancerMPact® Emerging
Technologies.

Bladder

Brain

Breast

Colorectal

Gastric
 Hodgkin’s Disease

Leukemia, Acute
Myeloid

Leukemia, Chronic
Lymphocytic

Leukemia, Chronic
Myeloid

Lung, Non-Small Cell

Lung, Small Cell

Lymphoma, Non-
Hodgkin’s

Melanoma

Multiple Myeloma

Ovarian

Pancreatic

Prostate

Renal Cell

Sarcoma

Thyroid
Emerging Technologies evaluates the key success factors and overall commercial viability of 47 of the most promising compounds in development for oncology indications. This report:

Includes detailed product profiles with analysis, development timeline assessments, and indication matrices

Evaluates drugs on an indication basis, focusing on Phase II or Phase III studies, and a summary of product highlights

Summarizes ongoing clinical trials and reviews published/presented clinical trial data
Three products are introduced in the Fall Update of Emerging Technologies
PRODUCTS ADDED TO CANCERMPACT GLOBAL 2012
EMERGING TECHNOLOGIES FALL EDITION
Product Name
BMS-936558
Ibrutinib
Rilotumumab
Developing Company(s)
Bristol-Myers Squibb
Pharmacyclics
Amgen
Mechanism
PD-1 antibody
BTK inhibitor
HGF antibody
As always, thank you for your continued support of Kantar Health and its reports and services. Please let us know if you have any questions about the report contents or methodologies. We welcome and encourage your feedback, and look forward to working with you in the future.
Best Regards,
The CancerMPact
®
team: Arnold DuBell , Christina Fish , Cory Blaiss , Corinne
Cusumano , Eric Miller , Jennifer Iverson , Josh Garcia , Mara Jeffress , Stephanie
Hawthorne , Tatiana Spicakova , Neesha Suvarna , Gregory Wolfe www.cancermpact.com
< http://www.cancermpact.com/ >